US Stock Market Move | Heart disease drug trial yields positive results, Cytokinetics (CYTK.US) surges over 20% in early trading.

On Tuesday, Cytokinetics (CYTK.US) soared over 20% in early trading, hitting a new high for the year at $79.72. On the news front, the company had previously announced positive preliminary results from its pivotal Phase 3 ACACIA-HCM trial, meeting two primary endpoints. The trial evaluated the efficacy of aficamten in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. This heart condition is characterized by thickening of the heart muscle leading to symptoms such as shortness of breath, fatigue, and chest pain, without significant blockage of blood flow. The trial showed statistically significant improvements compared to placebo in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and peak exercise performance, driving the stock surge after the announcement. Cytokinetics reported that ACACIA-HCM met its dual primary endpoints, showing significant improvement from baseline to week 36. Statistically significant improvements compared to placebo were observed in key secondary endpoints, including proportion of participants with improvement in New York Heart Association functional class, ventilatory efficiency, composite z-score for pVO2, and NT-proBNP.